



EASD NAFLD Study Group 4th Annual Meeting
Steno Diabetes Center, Denmark
4th-5th April 2016

Programme

MONDAY 4th APRIL 2016

08.30-09.00	REGISTRATION	
09.00-09.15	OPENING WORDS	
09.15-10.35	SESSION 1 – GUT-LIVER AXIS	
09.15-09.40	Amalia Gastaldelli Italy	Exenatide exerts its positive effects on liver by reducing both hepatic and adipose tissue insulin resistance
09.40-10.05	Paula Macedo Portugal	Impaired hepatic insulin clearance determines primary hyperinsulinemia in pre-diabetic stages
10.05-10.20	Irene Pierantonelli Italy	Lack of NLRP3-inflammasome leads to gut-liver axis derangement and increases hepatic injury in a mouse model of NAFLD
10.20-10.35	<i>Discussion</i>	
10.35-11.05	COFFEE BREAK	
11.05-12.15	SESSION 2 – LIVER DISEASE AND DIABETES MELLITUS 2	
11.05-11.30	Martijn Brouwers The Netherlands	NAFLD predicts the 10-year incidence of type 2 diabetes mellitus in familial combined hyperlipidemia
11.30-11.45	Louise Vedtofte Denmark	Decreased insulin sensitivity and increased waist circumference are independently associated with non-alcoholic fatty liver disease in women with previous gestational diabetes mellitus
11.45-12.00	Mostafa Elkady Egypt	Interplay between tumor necrosis factor- α , insulin resistance and T2DM in chronic hepatitis C Egyptian patients
12.00-12.15	<i>Discussion</i>	
12.15-13.15	LUNCH	
13.15-14.35	SESSION 3 – METABOLOMICS, LIPIDOMICS AND PROTEOMICS IN NAFLD	
13.15-13.40	Morten Karsdal Denmark	The adipokine Endotrophin measured in serum predicts response to two insulin sensitizers (PPAR γ agonists): improvement of the risk:benefit ratio for TZDs
13.40-14.05	Roy Taylor United Kingdom	Managing the vascular risk associated with NAFLD: VLDL1-TG production rate during effective dietary treatment to normalise liver fat
14.05-14.20	Panu Luukkonen Finland	De novo synthesized ceramides dissociate steatosis and insulin resistance in the human liver
14.20-14.35	<i>Discussion</i>	
14.35-15.00	COFFEE BREAK	
15.00-16.00	EASD/EASL/EASO NAFLD GUIDELINES – CURRENT STATUS & DISCUSSION	
	Jean-François Dufour (EASL) and Amalia Gastaldelli (EASD) on behalf of the guideline committee	
16.00-17.30	DISCUSSION OF FUTURE COLLABORATIVE FUNDING INITIATIVES	
	Amalia Gastaldelli on behalf of the study group steering committee	
18.25-19.00	BUS TRANSFER	
19.00	DINNER AT RESTAURANT NO. 2	



TUESDAY 5th APRIL 2016

09.00-10.35

SESSION 4 – INFLAMMATION IN LIVER DISEASE

09.00-09.25	Mette Nielsen Denmark	High serum levels of pro-peptide of type III collagen (PRO-C3) identify patients with progressive liver fibrosis and those most likely to benefit from anti-fibrotic therapy
09.25-09.50	Daniel Steinacher Austria	NorUDCA improves liver injury and glucose sensitivity in mouse models of obesity and steatosis
09.50-10.05	Paul Afolabi United Kingdom	The relationship between mitochondrial dysfunction and liver fibrosis in patients with NAFLD
10.05-10.20	Charlotte Green United Kingdom	Effect of glucose concentration on ER stress response and lipid metabolism in human liver cells
10.20-10.35	<i>Discussion</i>	

10.35-11.05

COFFEE BREAK

11.05-13.00

SESSION 5 – SYSTEMS APPROACHES TO STUDY NAFLD

11.05-11.30	Michael Krebs Austria	Lipid content and ATP metabolism in the liver of patients with acromegaly
11.30-11.55	Jussi Pihlajamäki Finland	Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin levels
11.55-12.10	Sara Heebøll Denmark	Circulating CD36 is correlated with intrahepatic lipid content in NAFLD patients
12.10-12.25	Serena Pelusi Italy	Clinical determinants of fibrosis progression in an Italian prospective cohort of patients with NAFLD
12.25-12.40	Elaina Maldonado United Kingdom	Development of a dynamic multi-scale, computational model of human hepatic glucose and fructose metabolism
12.40-13.00	<i>Discussion</i>	

13.00-14.00

LUNCH

14.00-14.30

MEETING CLOSURE

14.30-16.00

PLANNING OF FUTURE COLLABORATIVE INITIATIVES - CONTINUED

Each session consists of 1-2 Principal Investigator talks (20 min + 5 min for questions) and 1-3 Junior Research talks (10 min + 5 min for questions). Each session is ended with a discussion.

The meeting is kindly sponsored by Novo Nordisk A/S.

